Skip to Content

331 Results Found

  • Article
  • Open Access
2 Citations
1,543 Views
18 Pages

The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL

  • Joaquín Marco-Brualla,
  • Oscar Gonzalo,
  • Gemma Azaceta,
  • Isabel Izquierdo and ,
  • Luis Palomera,
  • Martín Villalba,
  • Isabel Marzo and
  • Alberto Anel
  • + 3 authors+ 0 author

29 August 2025

Since its discovery, the BTK inhibitor ibrutinib has redefined the standard treatments for hematological cancers, such as chronic lymphocytic leukemia (CLL). However, concerns exist regarding its secondary effects in humans and its occasional lack of...

(This article belongs to the Section Cellular Metabolism)
  • Article
  • Open Access
1 Citations
2,594 Views
17 Pages

Mice Overexpressing Wild-Type RRAS2 Are a Novel Model for Preclinical Testing of Anti-Chronic Lymphocytic Leukemia Therapies

  • Alejandro M. Hortal,
  • Ana Villanueva,
  • Irene Arellano,
  • Cristina Prieto and ,
  • Pilar Mendoza,
  • Xosé R. Bustelo and
  • Balbino Alarcón
  • + 2 authors+ 0 author

12 December 2023

B-cell chronic lymphocytic leukemia (B-CLL) is the most common type of leukemia in the Western world. Mutation in different genes, such as TP53 and ATM, and deletions at specific chromosomic regions, among which are 11q or 17p, have been described to...

(This article belongs to the Special Issue Advances in Chronic Lymphocytic Leukaemia (CLL) Research)
  • Review
  • Open Access
41 Citations
4,866 Views
20 Pages

MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia

  • Katerina Katsaraki,
  • Paraskevi Karousi,
  • Pinelopi I. Artemaki,
  • Andreas Scorilas and ,
  • Vasiliki Pappa,
  • Christos K. Kontos and
  • Sotirios G. Papageorgiou
  • + 2 authors+ 0 author

3 February 2021

MicroRNAs (miRNAs) represent a class of small non-coding RNAs bearing regulatory potency. The implication of miRNAs in physiological cellular processes has been well documented so far. A typical process orchestrated by miRNAs is the normal B-cell dev...

(This article belongs to the Special Issue MicroRNA and Cancer)
  • Article
  • Open Access
16 Citations
4,348 Views
20 Pages

Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

  • Mirco Di Marco,
  • Serena Veschi,
  • Paola Lanuti,
  • Alice Ramassone and ,
  • Stefania Pacillo,
  • Sara Pagotto,
  • Felice Pepe,
  • Jonahunnatha Nesson George-William,
  • Claudia Curcio and
  • Rosa Visone
  • + 18 authors+ 13 authors

12 January 2021

The clinical progression of B cell chronic lymphocytic leukemia (CLL) is associated with immune cell dysfunction and a strong decrease of miR-181b-5p (miR-181b), promoting the death of CLL cells. Here we investigated whether the reduction of miR-181b...

(This article belongs to the Special Issue Chronic Lymphocytic Leukaemia (CLL))
  • Article
  • Open Access
6 Citations
3,497 Views
16 Pages

A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome

  • Antoine Wagner,
  • Michèle Rouleau,
  • Lyne Villeneuve,
  • Trang Le and ,
  • Cheryl Peltier,
  • Éric P. Allain,
  • Caroline Beaudoin,
  • Sophie Tremblay,
  • Fréderic Courtier and
  • Chantal Guillemette
  • + 10 authors+ 5 authors

2 May 2023

In chronic lymphocytic leukemia (CLL), an elevated glycosyltransferase UGT2B17 expression (UGT2B17HI) identifies a subgroup of patients with shorter survival and poor drug response. We uncovered a mechanism, possibly independent of its enzymatic func...

(This article belongs to the Section Cell Signaling)
  • Article
  • Open Access
7 Citations
5,139 Views
20 Pages

Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients

  • Alicja Pacholewska,
  • Christina Grimm,
  • Carmen D. Herling,
  • Matthias Lienhard and ,
  • Anja Königs,
  • Bernd Timmermann,
  • Janine Altmüller,
  • Oliver Mücke,
  • Hans Christian Reinhardt and
  • Michal R. Schweiger
  • + 8 authors+ 3 authors

28 August 2021

Mutations in splicing factor genes have a severe impact on the survival of cancer patients. Splicing factor 3b subunit 1 (SF3B1) is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL); patients carrying these mutations have...

(This article belongs to the Special Issue Genetics and Epigenetics in Complex Diseases)
  • Review
  • Open Access
76 Citations
16,158 Views
24 Pages

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

  • Hilma J. van der Horst,
  • Inger S. Nijhof,
  • Tuna Mutis and
  • Martine E. D. Chamuleau

19 October 2020

Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades,...

(This article belongs to the Special Issue B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL))
  • Article
  • Open Access
11 Citations
3,817 Views
14 Pages

BTLA Expression in CLL: Epigenetic Regulation and Impact on CLL B Cell Proliferation and Ability to IL-4 Production

  • Lidia Karabon,
  • Anna Andrzejczak,
  • Lidia Ciszak,
  • Anna Tomkiewicz and ,
  • Aleksandra Szteblich,
  • Agnieszka Bojarska-Junak,
  • Jacek Roliński,
  • Dariusz Wołowiec,
  • Tomasz Wróbel and
  • Agata Kosmaczewska
  • + 5 authors+ 0 author

4 November 2021

In our previous study, while chronic lymphocytic leukemia (CLL) cases showed higher levels of B and T lymphocyte attenuator (BTLA) mRNA compared to controls, lower BTLA protein expression was observed in cases compared to controls. Hence we hypothesi...

(This article belongs to the Collection Trends and Advances in Tumor Immunology)
  • Article
  • Open Access
7 Citations
4,313 Views
15 Pages

Association of Common Variants of TNFSF13 and TNFRSF13B Genes with CLL Risk and Clinical Picture, as Well as Expression of Their Products—APRIL and TACI Molecules

  • Monika Jasek,
  • Agnieszka Bojarska-Junak,
  • Maciej Sobczyński,
  • Marta Wagner and ,
  • Sylwia Chocholska,
  • Jacek Roliński,
  • Dariusz Wołowiec and
  • Lidia Karabon
  • + 3 authors+ 0 author

6 October 2020

Interactions between APRIL (TNFSF13) and its receptor TACI (TNFRSF13B) are implicated in providing survival benefits for chronic lymphocytic leukaemia (CLL) cells. Here we explored the relationship between TNFSF13 and TNFRSF13B SNPs and expression of...

(This article belongs to the Special Issue The Study of Cancer Susceptibility Genes)
  • Article
  • Open Access
12 Citations
5,943 Views
15 Pages

B-Cell Activating Factor Enhances Hepatocyte-Driven Angiogenesis via B-Cell CLL/Lymphoma 10/Nuclear Factor-KappaB Signaling during Liver Regeneration

  • Chia-Hung Chou,
  • Cheng-Maw Ho,
  • Shou-Lun Lai,
  • Chiung-Nien Chen and ,
  • Yao-Ming Wu,
  • Chia-Tung Shun,
  • Wen-Fen Wen and
  • Hong-Shiee Lai
  • + 3 authors+ 0 author

10 October 2019

B-cell activating factor (BAFF) is found to be associated with the histological severity of nonalcoholic steatohepatitis (NASH). BAFF was also found to have a protective role in hepatic steatosis via down regulating the expression of steatogenesis ge...

(This article belongs to the Special Issue Wound Repair and Regeneration: Mechanisms, Signaling)
  • Commentary
  • Open Access
3,151 Views
10 Pages

7 August 2024

Chronic Lymphocytic Leukemia (CLL) is caused by the clonal expansion of CD5+ B lymphocytes in the circulation, peripheral lymphoid organs and bone marrow [...]

  • Case Report
  • Open Access
1 Citations
3,108 Views
7 Pages

Challenges in Diagnosis and Clinical Management of COVID-19 in Patient with B-Cell Chronic Lymphocytic Leukemia (CLL): Report of One Case

  • Vincenzo Visco,
  • Maria Enrichetta Lippi,
  • Gerardo Salerno,
  • Maria Angela Vittoria A. C. Licata and ,
  • Chiara de Dominicis,
  • Giusy Antolino,
  • Giacinto La Verde,
  • Iolanda Santino,
  • Maurizio Simmaco and
  • Salvatore Sciacchitano
  • + 5 authors+ 0 author

We report here a case of a patient affected by B-cell chronic lymphocytic leukemia (CLL) that developed COVID-19 during the actual SARS-CoV-2 outbreak. The coexistence of CLL and COVID-19 raises many questions regarding the possible increased risk of...

  • Review
  • Open Access
7 Citations
10,022 Views
14 Pages

Cancer Stem Cells of Differentiated B-Cell Malignancies: Models and Consequences

  • Emilie Gross,
  • Anne Quillet-Mary,
  • Loic Ysebaert,
  • Guy Laurent and
  • Jean-Jacques Fournie

25 March 2011

The concept of cancer stem cells has revolutionized our current vision of cancer development and was validated in solid tumors and cancers of the primitive hematopoietic compartment. Proof of the principle is still lacking, however, in malignancies o...

(This article belongs to the Special Issue Cancer Stem Cells)
  • Case Report
  • Open Access
3,170 Views
9 Pages

Rare Coexistence of Atypical Chronic Lymphocytic Leukemia and B-Acute Lymphoblastic Leukemia in a Patient Followed Up for Monoclonal B-Cell Lymphocytosis

  • Fabio Bertani,
  • Francesco Faiella,
  • Claudia Di Franco,
  • Raffaella Milani and ,
  • Antonella Gualdoni,
  • Cinzia Fulceri and
  • Elena Costa
  • + 2 authors+ 0 author

7 August 2025

Monoclonal B Lymphocytosis (MBL) is considered the pre-malignant state of chronic lymphocytic leukemia (CLL) and atypical chronic lymphocytic leukemia (aCLL). Both entities are rarely found in association with other hematological tumors; still, they...

  • Article
  • Open Access
6 Citations
2,917 Views
14 Pages

Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling

  • Evan A. Mulligan,
  • Susan J. Tudhope,
  • Jill E. Hunter,
  • Arabella E. G. Clift and ,
  • Sarah L. Elliott,
  • Geoffrey P. Summerfield,
  • Jonathan Wallis,
  • Chris J. Pepper,
  • Barabara Durkacz and
  • Elaine Willmore
  • + 6 authors+ 1 author

26 September 2023

Background: Canonical NF-κB signalling by p65 (RelA) confers chemo-resistance and poor survival in chronic lymphocytic leukaemia (CLL). The role of non-canonical NF-κB signalling (leading to RelB and p52 subunit activation) in CLL is less...

(This article belongs to the Special Issue Targeting Signal Transduction Pathways in Cancer)
  • Review
  • Open Access
33 Citations
5,792 Views
26 Pages

Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role

  • Alessandro Allegra,
  • Caterina Musolino,
  • Alessandro Tonacci,
  • Giovanni Pioggia and ,
  • Marco Casciaro and
  • Sebastiano Gangemi
  • + 1 author+ 0 author

24 February 2020

B-cell chronic lymphocytic leukemia (B-CLL) is the main cause of mortality among hematologic diseases in Western nations. B-CLL is correlated with an intense alteration of the immune system. The altered functions of innate immune elements and adaptiv...

(This article belongs to the Special Issue Interleukin in Cancer Pathogenesis and Treatment)
  • Feature Paper
  • Article
  • Open Access
5 Citations
3,400 Views
13 Pages

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

  • Sandra Ballester,
  • Begoña Pineda,
  • Patricia Rodrigues,
  • Eduardo Tormo and ,
  • María José Terol and
  • Pilar Eroles
  • + 1 author+ 0 author

23 June 2020

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors geneti...

(This article belongs to the Section Human Genomics and Genetic Diseases)
  • Article
  • Open Access
13 Citations
4,826 Views
15 Pages

DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia

  • Katarzyna Szoltysek,
  • Carmela Ciardullo,
  • Peixun Zhou,
  • Anna Walaszczyk and ,
  • Elaine Willmore,
  • Vikki Rand,
  • Scott Marshall,
  • Andy Hall,
  • Christine J. Harrison and
  • Meera Soundararajan
  • + 6 authors+ 1 author

16 October 2020

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western World and it is characterized by a marked degree of clinical heterogeneity. An impaired balance between pro- and anti-apoptotic stimuli determines chemorefractoriness...

(This article belongs to the Special Issue Protein Kinases: Function, Substrates, and Implication in Diseases)
  • Review
  • Open Access
8 Citations
3,505 Views
23 Pages

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders

  • Andrea Duminuco,
  • Paola De Luca,
  • Gaia Stanzione,
  • Laura Anastasia Caruso and ,
  • Giulio Lavenia,
  • Salvatore Scarso,
  • Bruno Garibaldi,
  • Fanny Erika Palumbo,
  • Calogero Vetro and
  • Giuseppe Alberto Palumbo
  • + 5 authors+ 0 author

12 January 2026

BTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL. As a central mediator of B-cell receptor signaling and microenvironment interactions, BTK suppor...

(This article belongs to the Section Molecular Medicine)
  • Article
  • Open Access
1 Citations
2,730 Views
11 Pages

Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors

  • Bella V. Biderman,
  • Ekaterina B. Likold,
  • Nataliya A. Severina,
  • Tatiana N. Obukhova and
  • Andrey B. Sudarikov

20 February 2023

Chronic lymphocytic leukemia (CLL) is one of the most common B-cell malignancies in Western countries. IGHV mutational status is the most important prognostic factor for this disease. CLL is characterized by an extreme narrowing of the IGHV genes rep...

(This article belongs to the Special Issue Genetics of Blood Disorders)
  • Article
  • Open Access
4 Citations
2,367 Views
22 Pages

Association of Genetic Variants at the CDKN1B and CCND2 Loci Encoding p27Kip1 and Cyclin D2 Cell Cycle Regulators with Susceptibility and Clinical Course of Chronic Lymphocytic Leukemia

  • Lidia Ciszak,
  • Agata Kosmaczewska,
  • Edyta Pawlak,
  • Irena Frydecka and ,
  • Aleksandra Szteblich and
  • Dariusz Wołowiec
  • + 1 author+ 0 author

31 October 2024

Beyond the essential role of p27Kip1 and cyclin D2 in cell cycle progression, they are also shown to confer an anti-apoptotic function in peripheral blood (PB) lymphocytes. Although the aberrant longevity and expression of p27Kip1 and cyclin D2 in le...

(This article belongs to the Section Molecular Oncology)
  • Article
  • Open Access
2 Citations
3,659 Views
12 Pages

Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay

  • Selena Mimmi,
  • Domenico Maisano,
  • Vincenzo Dattilo,
  • Massimo Gentile and ,
  • Federico Chiurazzi,
  • Alessandro D’Ambrosio,
  • Annamaria Zimbo,
  • Nancy Nisticò,
  • Annamaria Aloisio and
  • Ileana Quinto
  • + 8 authors+ 3 authors

Chronic Lymphocytic Leukemia (CLL) is a heterogeneous disease characterized by variable clinical courses among different patients. This notion was supported by the possible coexistence of two or more independent CLL clones within the same patients, i...

(This article belongs to the Section Cancer Biology and Oncology)
  • Article
  • Open Access
10 Citations
4,616 Views
20 Pages

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

  • Erhan Aptullahoglu,
  • Jonathan P. Wallis,
  • Helen Marr,
  • Scott Marshall and ,
  • Nick Bown,
  • Elaine Willmore and
  • John Lunec
  • + 2 authors+ 0 author

Chronic lymphocytic leukemia (CLL) is a genetically and clinically heterogeneous malignancy affecting older individuals. There are a number of current treatment options for CLL, including monoclonal antibodies, targeted drugs, chemotherapy, and diffe...

(This article belongs to the Special Issue Advance in Targeted Cancer Therapy and Mechanisms of Resistance)
  • Article
  • Open Access
7 Citations
3,395 Views
15 Pages

Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia

  • Pramath Kakodkar,
  • Sanket More,
  • Kinga András,
  • Nikos Papakonstantinou and ,
  • Sharon Kelly,
  • Mohammad Adib Makrooni,
  • Csaba Ortutay and
  • Eva Szegezdi
  • + 3 authors+ 0 author

12 July 2020

Treatment of chronic lymphocytic leukemia has advanced substantially as our understanding of the kinase signal transduction pathways driven by the B cell receptor (BcR) has developed. Particularly, understanding the role of Bruton tyrosine kinase and...

  • Article
  • Open Access
9 Citations
6,169 Views
18 Pages

Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL

  • Rainer Hubmann,
  • Susanne Schnabl,
  • Mohammad Araghi,
  • Christian Schmidl and ,
  • André F. Rendeiro,
  • Martin Hilgarth,
  • Dita Demirtas,
  • Farghaly Ali,
  • Philipp B. Staber and
  • Medhat Shehata
  • + 8 authors+ 3 authors

18 June 2020

NOTCH signaling represents a promising therapeutic target in chronic lymphocytic leukemia (CLL). We compared the anti-neoplastic effects of the nuclear NOTCH2 inhibitor gliotoxin and the pan-NOTCH γ-secretase inhibitor RO4929097 in primary CLL...

(This article belongs to the Special Issue The Roles of Notch Signaling in Cancers)
  • Article
  • Open Access
5 Citations
3,231 Views
18 Pages

9 August 2023

Chronic lymphocytic leukemia (CLL) is known for its wide-ranging clinical and genetic diversity. The study aimed to assess the associations between copy number variations (CNVs) and various biological and clinical features, as well as the survival ra...

  • Article
  • Open Access
1 Citations
1,236 Views
15 Pages

Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort

  • Davide Bagnara,
  • Andrea Nicola Mazzarello,
  • Monica Colombo,
  • Ennio Nano and ,
  • Niccolò Cardente,
  • Fabiana Ferrero,
  • Nadia Bertola,
  • Vanessa Cossu,
  • Fabio Ghiotto and
  • Franco Fais
  • + 12 authors+ 7 authors

18 March 2026

Background/Objectives: The immunoglobulin heavy-chain variable (IGHV) gene repertoire represents a characteristic feature of chronic lymphocytic leukemia (CLL), although its configuration is not well defined at the early disease stages. The IGHV repe...

(This article belongs to the Section Antibody-Based Diagnostics)
  • Article
  • Open Access
1 Citations
3,628 Views
67 Pages

Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL)

  • James P. McKeown,
  • Andrew J. Byrne,
  • Sandra A. Bright,
  • Clara E. Charleton and ,
  • Shubhangi Kandwal,
  • Ivan Čmelo,
  • Brendan Twamley,
  • Anthony M. McElligott,
  • Darren Fayne and
  • Mary J. Meegan
  • + 7 authors+ 2 authors

5 August 2024

Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells, and it is the most frequent form of leukemia diagnosed in Western countries. It is characterized by the proliferation and accumulation of neoplastic B lymphocytes in the blood, lym...

(This article belongs to the Special Issue Advances in Pharmaceutical Sciences: In Honor of Dr. Jean Jacques Vanden Eynde (JJ))
  • Brief Report
  • Open Access
3 Citations
3,577 Views
8 Pages

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells

  • Subir Roy Chowdhury,
  • Cheryl Peltier,
  • Sen Hou,
  • Amandeep Singh and ,
  • James B. Johnston,
  • Spencer B. Gibson,
  • Aaron J. Marshall and
  • Versha Banerji
  • + 3 authors+ 0 author

19 January 2021

Mitochondrial respiration is becoming more commonly used as a preclinical tool and potential biomarker for chronic lymphocytic leukemia (CLL) and activated B-cell receptor (BCR) signaling. However, respiration parameters have not been evaluated with...

(This article belongs to the Special Issue Novel Drug Targets and Advances in Treatment of CLL)
  • Article
  • Open Access
8 Citations
3,753 Views
13 Pages

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors

  • Erika Rimondi,
  • Elisabetta Melloni,
  • Arianna Romani,
  • Veronica Tisato and ,
  • Fabio Casciano,
  • Gian Matteo Rigolin,
  • Daniela Milani,
  • Claudio Celeghini,
  • Giorgio Zauli and
  • Rebecca Voltan
  • + 6 authors+ 1 author

1 July 2021

In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvironment promotes tumor cell survival. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is one of the first-in-class molecules for the treatment o...

(This article belongs to the Special Issue Chronic Lymphocytic Leukemia: Therapy and Outcome)
  • Article
  • Open Access
1 Citations
1,720 Views
19 Pages

Analysis of Stereotyped B-Cell Receptor Frequencies Among Portuguese De Novo-Diagnosed Chronic Lymphocytic Leukemia Patients (PAIS Study)

  • Daniela Alves,
  • Gisela Ferreira,
  • Joana Caldas,
  • Mariana Fernandes and ,
  • Cátia Gaspar,
  • Mafalda Alpoim,
  • Inês Carvalhais,
  • Sara Duarte,
  • Helena Silva and
  • João Raposo
  • + 16 authors+ 11 authors

14 April 2025

Background/Objectives: Chronic lymphocytic leukemia (CLL) exhibits a heterogeneous clinical course influenced by genetic factors, such as the mutational status of immunoglobulin variable regions (IGHV). Recently, B-cell receptor (BcR) stereotypes hav...

(This article belongs to the Special Issue Hematologic Malignancies and Related Disorders: Challenges from Diagnosis to Treatment)
  • Review
  • Open Access
1,421 Views
17 Pages

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

  • Eduardo Bravo,
  • Claudia Cabrera Pastrana,
  • Erica N. Lamkin,
  • Katarzyna Ciurko and
  • Justin Taylor

31 July 2026

Kinases are highly explored drug targets due to their central role in cell growth, differentiation, and cell death, as well as their relationship to cancer initiation and progression. However, with more than 500 kinases in the human kinome and signif...

(This article belongs to the Special Issue Cellular Pathology: Emerging Discoveries and Perspectives in the USA)
  • Review
  • Open Access
12 Citations
5,536 Views
30 Pages

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma

  • Jaco A. C. van Bruggen,
  • Anne W. J. Martens,
  • Sanne H. Tonino and
  • Arnon P. Kater

18 December 2020

The next frontier towards a cure for B-cell non-Hodgkin lymphomas (B-NHL) is autologous cellular immunotherapy such as immune checkpoint blockade (ICB), bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cells. While highly successfu...

(This article belongs to the Special Issue B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL))
  • Article
  • Open Access
14 Citations
4,291 Views
17 Pages

RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model

  • Hana Svozilová,
  • Zdeněk Plichta,
  • Vladimír Proks,
  • Radana Studená and ,
  • Jiří Baloun,
  • Michael Doubek,
  • Šárka Pospíšilová and
  • Daniel Horák
  • + 3 authors+ 0 author

27 February 2021

Superporous poly(2-hydroxyethyl methacrylate-co-2-aminoethyl methacrylate) (P(HEMA-AEMA)) hydrogel scaffolds are designed for in vitro 3D culturing of leukemic B cells. Hydrogel porosity, which influences cell functions and growth, is introduced by a...

(This article belongs to the Special Issue Hydrogels in Regenerative Medicine and Other Biomedical Applications)
  • Article
  • Open Access
14 Citations
5,336 Views
17 Pages

Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms

  • Adrián Mosquera Orgueira,
  • Miguel Cid López,
  • Andrés Peleteiro Raíndo,
  • José Ángel Díaz Arias and ,
  • Beatriz Antelo Rodríguez,
  • Laura Bao Pérez,
  • Natalia Alonso Vence,
  • Ángeles Bendaña López,
  • Aitor Abuin Blanco and
  • José Luis Bello López
  • + 11 authors+ 6 authors

16 March 2021

There is growing evidence indicating the implication of germline variation in cancer predisposition and prognostication. Here, we describe an analysis of likely disruptive rare variants across the genomes of 726 patients with B-cell lymphoid neoplasm...

(This article belongs to the Special Issue Inside Cancer Genomics: From Structure to Therapy)
  • Article
  • Open Access
2 Citations
3,615 Views
18 Pages

Distinct NF-kB Regulation Favors a Synergic Action of Pevonedistat and Laduviglusib in B-Chronic Lymphocytic Leukemia Cells Ex Vivo

  • Víctor Arenas,
  • Jose Luis Castaño,
  • Juan José Domínguez,
  • Lucrecia Yáñez and
  • Carlos Pipaón

5 February 2025

Background/Objectives: Chronic lymphocytic leukemia (CLL) remains an incurable B-cell malignancy. B-CLL cells exhibit an extended lifespan in part due to the activation of survival pathways such as NF-kB. A crosstalk between NF-kB and GSK-3β pat...

(This article belongs to the Section Molecular Cancer Biology)
  • Review
  • Open Access
38 Citations
8,175 Views
22 Pages

Immunomodulatory Drugs for the Treatment of B Cell Malignancies

  • Nikolaos Ioannou,
  • Khushi Jain and
  • Alan G. Ramsay

Accumulating evidence suggests that the tumor microenvironment (TME) is involved in disease progression and drug resistance in B cell malignancies, by supporting tumor growth and facilitating the ability of malignant cells to avoid immune recognition...

(This article belongs to the Special Issue Tumor Microenvironment from a Precision Medicine Perspective)
  • Article
  • Open Access
5 Citations
4,329 Views
15 Pages

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors

  • Andrej Besse,
  • Marianne Kraus,
  • Max Mendez-Lopez,
  • Elmer Maurits and ,
  • Herman S. Overkleeft,
  • Christoph Driessen and
  • Lenka Besse
  • + 2 authors+ 0 author

1 March 2022

Targeting proteasome with proteasome inhibitors (PIs) is an approved treatment strategy in multiple myeloma that has also been explored pre-clinically and clinically in other hematological malignancies. The approved PIs target both the constitutive a...

(This article belongs to the Special Issue The Immunoproteasome in Health and Disease)
  • Article
  • Open Access
24 Citations
10,323 Views
10 Pages

Poly[3-(3,4-dihydroxyphenyl)glyceric Acid], A New Biologically Active Polymer from Symphytum Asperum Lepech. and S.Caucasicum Bieb. (Boraginaceae)

  • V. Barbakadze,
  • E. Kemertelidze,
  • I. Targamadze,
  • K. Mulkijanyan and ,
  • A. Shashkov and
  • A. Usov
  • + 1 author+ 0 author

30 September 2005

Two high-molecular water-soluble preparations with high anticomplementary, antioxidant, antilipoperoxidant and antiinflammatory activities were isolated from the roots of Symphytum asperum and S. caucasicum. Their main chemical constituent was found...

(This article belongs to the Special Issue Selected Papers from the “2nd International Conference on Natural Products and Physiologically Active Substances” (ICNPAS-2004) and the 3rd EuroAsian Heterocyclic Meeting “Heterocycles in Organic and Combinatorial Chemistry”)
  • Article
  • Open Access
18 Citations
5,810 Views
18 Pages

Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells

  • Simon Latour,
  • Marion Zanese,
  • Valérie Le Morvan,
  • Anne-Marie Vacher and ,
  • Nelly Menard,
  • Fontanet Bijou,
  • Francoise Durrieu,
  • Pierre Soubeyran,
  • Ariel Savina and
  • Laurence Bresson-Bepoldin
  • + 6 authors+ 1 author

1 March 2019

GA101/obinutuzumab is a novel type II anti-CD20 monoclonal antibody (mAb), which is more effective than rituximab (RTX) in preclinical and clinical studies when used in combination with chemotherapy. Ca2+ signaling was shown to play a role in RTX-ind...

(This article belongs to the Special Issue Ion Channels in Cancer)
  • Review
  • Open Access
13 Citations
6,896 Views
12 Pages

Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins

  • Mehmet Kemal Tur,
  • Adebukola K. Daramola,
  • Stefan Gattenlöhner,
  • Marco Herling and ,
  • Shivan Chetty and
  • Stefan Barth
  • + 1 author+ 0 author

Targeted cancer immunotherapy is designed to selectively eliminate tumor cells without harming the surrounding healthy tissues. The death-associated protein kinases (DAPk) are a family of proapoptotic proteins that play a vital role in the regulation...

(This article belongs to the Special Issue Immuno-Active Cancer Therapeutics)
  • Case Report
  • Open Access
1 Citations
1,289 Views
14 Pages

Chronic Glomerular Thrombotic Microangiopathy in a 72-Year-Old Patient with B-Cell Chronic Lymphocytic Leukemia and IgG Lambda Paraprotein

  • László Bitó,
  • Timea Gurbity Pálfi,
  • Krisztina Jost,
  • Simon Péter Nagy and ,
  • Zoltán Prohászka and
  • Béla Iványi
  • + 1 author+ 0 author

23 October 2025

The cause of nephrotic–nephritic syndrome and elevated blood pressure values was investigated by renal biopsy in a 72-year-old Caucasian male with B-cell chronic lymphocytic leukemia (B-CLL) and a low level of IgG/lambda paraprotein. Double-con...

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
84 Citations
16,288 Views
23 Pages

B-cell receptor (BCR) is a B cell hallmark surface complex regulating multiple cellular processes in normal as well as malignant B cells. Igα (CD79a)/Igβ (CD79b) are essential components of BCR that are indispensable for its functionality,...

(This article belongs to the Section Molecular Oncology)
  • Review
  • Open Access
34 Citations
10,098 Views
16 Pages

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects

  • Andrea Härzschel,
  • Antonella Zucchetto,
  • Valter Gattei and
  • Tanja Nicole Hartmann

Lineage commitment and differentiation of hematopoietic cells takes place in well-defined microenvironmental surroundings. Communication with other cell types is a vital prerequisite for the normal functions of the immune system, while disturbances i...

(This article belongs to the Special Issue The Importance of Tumor-Host Interactions in Adult B-Cell Leukemias and Lymphomas)
  • Review
  • Open Access
44 Citations
8,791 Views
26 Pages

With the introduction of next generation sequencing methods, such as RNA sequencing, it has become apparent that alterations in the non-coding regions of our genome are important in the development of cancer. Particularly interesting is the class of...

(This article belongs to the Special Issue Non-Coding RNAs and Epigenetics in Cancer & Selected Papers from the 2nd International Symposium on Frontiers in Molecular Science)
  • Article
  • Open Access
10 Citations
4,323 Views
16 Pages

Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis

  • Michael Constantinides,
  • Alexis Fayd’herbe De Maudave,
  • Marie Potier-Cartereau,
  • Mauricio Campos-Mora and ,
  • Guillaume Cartron and
  • Martin Villalba
  • + 1 author+ 0 author

9 February 2023

CD20 monoclonal antibodies (mAbs) eliminate B cells in several clinical contexts. At least two of these Abs, obinutuzumab (OBI) and rituximab (RTX), induce quick elimination of targets and put cancer patients at risk of tumor lysis syndrome (TLS) wit...

(This article belongs to the Special Issue Oncology: State-of-the-Art Research in Spain)
  • Feature Paper
  • Review
  • Open Access
9 Citations
7,439 Views
14 Pages

Complement Activation in the Treatment of B-Cell Malignancies

  • Clive S. Zent,
  • Jonathan J. Pinney,
  • Charles C. Chu and
  • Michael R. Elliott

1 December 2020

Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-de...

(This article belongs to the Special Issue The Role of Complement in Cancer Immunotherapy)
  • Article
  • Open Access
6 Citations
4,707 Views
24 Pages

3 July 2022

Transcriptional regulator BCL11A plays a crucial role in coordinating a suite of developmental processes including skin morphogenesis, barrier functions and lipid metabolism. There is little or no reports so far documenting the role of BCL11A in post...

(This article belongs to the Special Issue Retinoic Acid and Retinoid X Receptors)
  • Review
  • Open Access
3 Citations
3,216 Views
14 Pages

Increased c-MYC Expression Associated with Active IGH Locus Rearrangement: An Emerging Role for c-MYC in Chronic Lymphocytic Leukemia

  • Kenza Guiyedi,
  • Milène Parquet,
  • Said Aoufouchi,
  • Jasmine Chauzeix and ,
  • David Rizzo,
  • Israa Al Jamal,
  • Jean Feuillard,
  • Nathalie Gachard and
  • Sophie Peron
  • + 4 authors+ 0 author

6 November 2024

This review examines the pivotal role of c-MYC in Chronic Lymphocytic Leukemia (CLL), focusing on how its overexpression leads to increased genetic instability, thereby accelerating disease progression. MYC, a major oncogene, encodes a transcription...

(This article belongs to the Special Issue Oncogenesis of Lymphoma)

of 7